You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Dasatinib, CML-CP

Showing 1 - 25 of 1,744
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Among CP-CML Participants Initiating Dasatinib inReal Life

Completed
  • Chronic Myeloid Leukemia
  • Non-Interventional
  • Paris, France
    Local Institution
Jun 17, 2022

Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

Recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid

Recruiting
  • CML-CP; Mutation;Suboptimal Response or Failure in TKI
  • Wuhan, Hubei, China
    Weiming Li
May 31, 2021

Chronic Myelogenous Leukemia - Chronic Phase Trial in China (Dasatinib Tablets)

Completed
  • Chronic Myelogenous Leukemia - Chronic Phase
  • Dasatinib Tablets
  • Shenzhen, Guangdong, China
  • +3 more
Jun 11, 2021

Early Conversion of Dasatinib in CML-CP Patients

Enrolling by invitation
  • Validity and Safety
  • Dasatinib 100 MG
  • Guangzhou, Guangdong, China
    NanfangH
Dec 9, 2020

Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Treatment-free Remission
  • TFR(Treatment-Free Remission)
  • (no location specified)
Jun 27, 2022

Chronic Phase Chronic Myeloid Leukemia Trial in Worldwide (Dasatinib)

Completed
Has Results
  • Chronic Phase Chronic Myeloid Leukemia
  • Duarte, California
  • +27 more
Dec 7, 2021

Withdrawal of Second-generation Tyrosine Kinase Inhibitors After

Recruiting
  • MMR on 12 Month
  • Guangzhou, Guangdong, China
  • +1 more
Apr 21, 2022

Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Completed
  • Chronic Myeloid Leukemia
  • 3L Therapy
  • T315I
  • Lyon, France
    Novartis Investigative Site
Nov 9, 2022

3rd Line Therapy or More to Treat Adult CML- CP in Real World

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Asciminib
  • (no location specified)
Oct 16, 2023

B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Chicago, Illinois
  • +5 more
Dec 27, 2021

Withdrawal or Reduction TKIs in CML-CP

Recruiting
  • MMR on 12 Month
  • withdrawal TKIs or halve TKIs
  • Guangzhou, Guangdong, China
    NanfangH
Sep 2, 2021

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Bordeaux, Aquitaine, France
  • +11 more
Dec 6, 2020

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting
  • Flumatinib
  • +2 more
  • Shenzhen, Guangdong, China
    The Second People's Hospital of Shenzhen
Mar 15, 2022

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Jun 24, 2022

Chronic Myeloid Leukemia Trial in Worldwide (KRT-232, Dasatinib, Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia
  • Birmingham, Alabama
  • +25 more
Mar 4, 2022

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Trial in Worldwide (Imatinib, Nilotinib, Bosutinib)

Recruiting
  • Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
  • Longmont, Colorado
  • +128 more
Aug 1, 2022

Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission Trial

Recruiting
  • Chronic Myeloid Leukemia
  • +2 more
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
  • Houston, Texas
  • +3 more
Jan 25, 2022

BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib

Active, not recruiting
  • Chronic Myeloid Leukemia
  • Dasatinib discontinuation
  • Rionero in Vulture, Potenza, Italy
  • +36 more
Jan 4, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia Trial in Worldwide (nilotinib)

Completed
Has Results
  • Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
  • Loma Linda, California
  • +35 more
Mar 25, 2021

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

Not yet recruiting
  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
  • (no location specified)
Jul 11, 2022

Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Trial in Worldwide (ABL001, ABL001 +

Active, not recruiting
  • Chronic Myelogenous Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
  • Boston, Massachusetts
  • +18 more
Jan 19, 2023

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022